Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma

Takihata,Yasuhiro; Einama,Takahiro; Kobayashi,Kazuki; Suzuki,Takafumi; Yonamine,Naoto; Fujinuma,Ibuki; Tsunenari,Takazumi; Yamagishi,Yoji; Iwasaki,Toshimitsu; Miyata,Yoichi; Shinto,Eiji; Ogata,Sho; Tsujimoto,Hironori; Ueno,Hideki; Kishi,Yoji

doi:10.3892/ol.2021.12675

Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma

Authors:
- Yasuhiro Takihata
- Takahiro Einama
- Kazuki Kobayashi
- Takafumi Suzuki
- Naoto Yonamine
- Ibuki Fujinuma
- Takazumi Tsunenari
- Yoji Yamagishi
- Toshimitsu Iwasaki
- Yoichi Miyata
- Eiji Shinto
- Sho Ogata
- Hironori Tsujimoto
- Hideki Ueno
- Yoji Kishi
View Affiliations

Affiliations: Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan, Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
Published online on: March 23, 2021 https://doi.org/10.3892/ol.2021.12675
Article Number: 414
Copyright: © Takihata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have suggested that the interaction of mesothelin (MSLN) and cancer antigen 125 (CA125) enhances tumor metastases. The aim of the present study was to clarify the impact of MSLN and CA125 co‑expression on the prognosis of patients with extrahepatic bile duct carcinoma (BDC). Tissue samples from patients who underwent surgical resection between 2007 and 2015 for perihilar or distal BDC were immunohistochemically examined. The expression levels of MSLN and CA125 in tumor cells were analyzed. The expression in <50% and ≥50% of the total tumor cells were defined as low‑ and high‑level expression, respectively. Tissue samples were obtained from 31 patients with perihilar BDC and 43 patients with distal BDC. Lymph node metastases were associated with MSLN and CA125 co‑expression in patients with perihilar BDC (P=0.002), while there was no association between lymph node metastasis and co‑expression in patients with distal BDC (P=0.362). MSLN and CA125 co‑expression was associated with a worse overall survival rate in patients with perihilar BDC (5‑year overall survival rate, co‑expression positive vs. negative, 24 vs. 63%; P=0.038). To the best of our knowledge, the present study is the first to report an association between co‑expression of MSLN and CA125 with a poor prognosis in patients with perihilar BDC. The current findings suggested that the significance of co‑expression differed according to the BDC location.

View Figures

View References

1	Brierley JD, Gospodarowicz MK and Wittekind C: Digestive system tumours. TNM Classification of Malignant Tumours. 8th edition. Wiley-Blackwell; Oxford: pp. 83–90. 2017
2	Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hoyos S, Navas MC, Restrepo JC and Botero RC: Current controversies in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 1864:1461–1467. 2018. View Article : Google Scholar : PubMed/NCBI
4	Khan SA, Tavolari S and Brandi G: Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39 (Suppl 1):19–31. 2019. View Article : Google Scholar : PubMed/NCBI
5	Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H and Nagano H: Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 3:378–389. 2019. View Article : Google Scholar : PubMed/NCBI
6	Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I and Willingham MC: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 16:259–268. 1992. View Article : Google Scholar : PubMed/NCBI
7	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
8	Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
9	Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428. 2003. View Article : Google Scholar : PubMed/NCBI
10	Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T and Pastan I: Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 11:3814–3820. 2005. View Article : Google Scholar : PubMed/NCBI
11	Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, et al: Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
12	Hassan R, Bera T and Pastan I: Mesothelin: A new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
13	Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M and Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 279:9190–9198. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B and Ho M: A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 284:3739–3749. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, et al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 5:502006. View Article : Google Scholar : PubMed/NCBI
16	Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A, et al: Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 41:2109–2118. 2012. View Article : Google Scholar : PubMed/NCBI
17	Nomura R, Fujii H, Abe M, Sugo H, Ishizaki Y, Kawasaki S and Hino O: Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. Int Surg. 98:164–169. 2013. View Article : Google Scholar : PubMed/NCBI
18	He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ and Rojanasakul Y: Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer. 16:632017. View Article : Google Scholar : PubMed/NCBI
19	Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, et al: C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol. 49:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Bo X, Nan L, Wang CC, Gao Z, Suo T, Ni X, Liu H, Lu P, Wang Y, et al: Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010–2016. Cancer Med. 9:1335–1348. 2020. View Article : Google Scholar : PubMed/NCBI
22	Hasebe T, Konishi M, Iwasaki M, Endoh Y, Nakagohri T, Takahashi S, Kinoshita T and Ochiai A: Histological characteristics of tumor cells and stromal cells in vessels and lymph nodes are important prognostic parameters of extrahepatic bile duct carcinoma: A prospective study. Hum Pathol. 36:655–664. 2005. View Article : Google Scholar : PubMed/NCBI
23	Noji T, Miyamoto M, Kubota KC, Shinohara T, Ambo Y, Matsuno Y, Kashimura N and Hirano S: Evaluation of extra capsular lymph node involvement in patients with extra-hepatic bile duct cancer. World J Surg Oncol. 10:1062012. View Article : Google Scholar : PubMed/NCBI
24	Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, et al: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chen SH, Hung WC, Wang P, Paul C and Konstantopoulos K: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 3:18702013. View Article : Google Scholar : PubMed/NCBI
26	Ishida K, Osakabe M, Eizuka M, Tai S, Sugimoto R, Fujita Y, Katagiri H, Takahara T, Uesugi N, Nitta H, et al: The expression of gastrointestinal differentiation markers in extrahepatic cholangiocarcinoma: Clinicopathological significance based on tumor location. Hum Pathol. 92:91–100. 2019. View Article : Google Scholar : PubMed/NCBI
27	Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et al: Genomic spectra of biliary tract cancer. Nat Genet. 47:1003–1010. 2015. View Article : Google Scholar : PubMed/NCBI